家族性腺腫性ポリポーシス治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Familial Adenomatous Polyposis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0775
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Familial Adenomatous Polyposis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis – Pipeline Review, H1 2020, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis  (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 9 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis – Overview
Familial Adenomatous Polyposis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis – Companies Involved in Therapeutics Development
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Emtora Biosciences
FunPep Co Ltd
GLW Pharma
Johnson & Johnson
Recursion Pharmaceuticals Inc
Shanghai Haishi Biopharmaceutical Co Ltd
Stemsynergy Therapeutics Inc
TherapyX Inc
Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis – Drug Profiles
(eflornithine hydrochloride + sulindac) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXONC-57 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAPXIL SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guselkumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosapent ethyl – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interleukin-10 SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
magnesium lysinate bis eicosapentaenoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMX-1002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic peptide for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Familial Adenomatous Polyposis – Dormant Projects
Familial Adenomatous Polyposis – Discontinued Products
Familial Adenomatous Polyposis – Product Development Milestones
Featured News & Press Releases
Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx
Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis
Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference
May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis
Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis
Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps
Dec 10, 2018: Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis
Nov 19, 2018: Cancer Prevention Pharmaceuticals to present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018
Oct 22, 2018: Marc L. Tokars Joins Cancer Prevention Pharmaceuticals as Vice President of Clinical and Regulatory Affairs
Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance
Nov 21, 2017: Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Sep 18, 2017: FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, H1 2020
Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by GLW Pharma, H1 2020
Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, H1 2020
Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H1 2020
Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, H1 2020
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H1 2020
Familial Adenomatous Polyposis - Dormant Projects, H1 2020
Familial Adenomatous Polyposis - Discontinued Products, H1 2020

【掲載企業】

Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Emtora Biosciences
FunPep Co Ltd
GLW Pharma
Johnson & Johnson
Recursion Pharmaceuticals Inc
Shanghai Haishi Biopharmaceutical Co Ltd
Stemsynergy Therapeutics Inc
TherapyX Inc
Thetis Pharmaceuticals LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[家族性腺腫性ポリポーシス治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆